LifeCell is a biotechnology company that develops and sells tissue grafts and become a leader in the field of regenerative medicine. In recent years, LifeCell's sales have grown at an average of 41% per year and profits up to 72% annually, due in part to rising sales of their human tissue product AlloDerm. In more recent years, sales have stabilized at 12% annually. AlloDerm is used during surgeries ranging from complex hernia repairs to breast reconstruction.
In 2006, LifeCell became associated with an incident involving the alleged harvesting of tissue from deceased individuals who never consented to become donors. After an investigation by the Brooklyn District Attorney, four individuals were indicted. Although, LifeCell played an integral part in exposing the illegal tissue harvesting, LifeCell was the recipient of cadaver material from the aforementioned tissue bank and has been named in a number of lawsuits. The company has pledged to defend itself against the lawsuits and claims it has not received any reports of disease transmission.
Acquisition by KCI
In early April 2008, Kinetic Concepts Inc (KCI), a company specializing in advanced wound care and therapeutic support systems, announced its intention to acquire LifeCell in a non-hostile transaction for $1.7 billion. LifeCell will become a wholly owned subsidiary of KCI during the second quarter of 2008. Its CEO, Paul Thomas, will become President of the LifeCell division of KCI. LifeCell's headquarters will remain in Branchburg, New Jersey. KCI is headquartered in San Antonio, Texas. Currently, LifeCell, KCI, and Systagenix operate under one global medical technology brand known as Acelity.
- . Hot Growth Special Report 2006.BusinessWeek. Retrieved on May 31, 2007.